10 results
DEFA14A
EX-99.1
IMVT
Immunovant Inc
29 Oct 19
Additional proxy soliciting materials
1:50pm
be the optimal outcome for society and for shareholders. I would think this is more likely to be the case now than at any time in the last couple of decades
8-K
EX-99.1
IMVT
Immunovant Inc
29 Oct 19
This report is prepared solely for the use of John Strumbos
1:48pm
be the optimal outcome for society and for shareholders. I would think this is more likely to be the case now than at any time in the last couple of decades
8-K
EX-99.1
IMVT
Immunovant Inc
8 Dec 22
Regulation FD Disclosure
7:06am
Demyelinating Polyneuropathy; EAN/PNS = European Academy of Neurology/Peripheral Nerve Society; Ig = immunoglobulin (IVIG and SCIG) therapy; IMP
8-K
EX-99.1
IMVT
Immunovant Inc
7 Sep 22
Regulation FD Disclosure
6:39am
of Neurology/Peripheral Nerve Society; Ig = immunoglobulin (IVIG and SCIG) therapy; IMP = investigational medicinal product; LTE = Long-term Extension
424B4
IMVT
Immunovant Inc
10 May 19
Prospectus supplement with pricing info
5:18pm
and a director of Neurogene, Inc. since February 2019. In addition, Dr. Nagendran is a founding member of the Robert Wood Johnson Legacy Society and also … , Inc. since February 2019. In addition, Dr. Nagendran is a founding member of the Robert Wood Johnson Legacy Society and also the sponsor
DRS
9yuou9fm71umu5rmbdw6
23 Jan 19
Draft registration statement
12:00am
S-1
fvw721m5ynjiqg
15 Apr 19
IPO registration
9:56pm
DRS/A
5j2ss w6kzy
26 Feb 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next